(Q53538620)

15 May 2018

title

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. (English)

1 reference

15 May 2018

main subject

cinacalcet hydrochloride

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

Daisuke Nakashima

1

1 reference

15 May 2018

Hirotaka Takama

2

1 reference

15 May 2018

Yuko Ogasawara

3

1 reference

15 May 2018

Tetsuyoshi Kawakami

4

1 reference

15 May 2018

Tsuyoshi Nishitoba

5

1 reference

15 May 2018

Sakuo Hoshi

6

1 reference

15 May 2018

Eiji Uchida

7

1 reference

15 May 2018

Hideji Tanaka

8

1 reference

15 May 2018

publication date

24 July 2007

1 reference

15 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

15 May 2018

volume

47

1 reference

15 May 2018

issue

10

1 reference

15 May 2018

page(s)

1311-1319

1 reference

15 May 2018

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Calcimimetics: therapeutic potential in hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

In vitro approaches to predicting drug interactions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Inhibition and induction of human cytochrome P450 (CYP) enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007304103

21 January 2018

Identifiers

DOI

10.1177/0091270007304103

1 reference

15 May 2018

1 reference

15 May 2018